Citations

Institution: Mayo Clinic Clear

Showing 10 of 107885 citations.

Analysis of gene expression changes upon topobexin treatment and TOP2B-knockout in hiPSC-derived cardiomyocytes
Keresteš, Veronika , Cowell, Ian G. , Jirkovská, Anna , Khazeem, Mushtaq M. , Karabanovich, Galina , Melnikova, Iuliia , Casement, John , Šimůnek, Tomáš , Schellenberg, Matthew J. , Creigh, Adam R. , Yang, Chunbo, Cowell, Ian , Khazeem, Mushtaq , Kubes, Jan , Simunek, Tomas , Roh, Jaroslav , Schellenberg, Matthew , Creigh, Adam , Yang, Chunbo , Lako, Majlinda , Armstrong, Lyle , Austin, Caroline

Biology Open | July 23, 2026 | Volume: 15 | Issue: 8 | Pages: No page available

10.1242/bio.062592 | PMID 42489567 Get It

ABSTRACT The role of DNA topoisomerase II beta (TOP2B) in cardiomyocyte differentiation is poorly understood. To address this, human induced pluripotent stem cells (hiPSC) were differentiated into cardiomyocytes (CM) that were wild type (WT) or contained a genomic deletion of Topoisomerase 2B (BKO). Both WT and BKO hiPSC could be induced to differentiate into sheets of beating cardiomyocytes. BKO hiPSC take slightly longer to differentiate into sheets of beating CM than WT iPSC. RNA was prepared from both undifferentiated and differentiated WT and BKO hiPSC. RNA-seq was used to examine gene expression changes when the WT and BKO hiPSC were differentiated into CM. Gene expression changes following differentiation of BKO cells were largely similar to those in WT cells. In addition, the differentiated WT CM were treated with dexrazoxane (ICRF-187), a TOP2 catalytic inhibitor that targets both TOP2A and TOP2B, or topobexin, a new TOP2B selective catalytic inhibitor. Topobexin inhibition partially phenocopied a TOP2B deletion and thereby providing an alternative to TOP2B gene knockout in many cell lines. In future, hiPSC derived CM with and without TOP2B and inhibition by topobexin ex vivo CM could be used to study anthracycline-induced cardiotoxicity and to screen for cardioprotectants.
Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis
Vigiser, Ifat , Zeevi, Yoav, Piura, Yoav, Kolb, Hadar , Golan, Maya, Karni, Arnon , Regev, Keren , Zeevi, Yoav , Piura, Yoav , Golan, Maya

Multiple Sclerosis Journal – Experimental, Translational and Clinical | July 23, 2026 | Volume: 12 | Issue: 3 | Pages: No page available

10.1177/20552173261471723 | PMID 42499404 Get It

Background Reliable biomarkers of inflammatory activity in multiple sclerosis (MS) are needed to complement clinical and MRI assessments. Circulating microRNAs (miRNAs) are promising candidates due to their serum stability and involvement in MS-related biological pathways. Objectives To evaluate whether selected serum miRNAs can discriminate relapse from remission in treatment-naive patients with relapsing-remitting MS (RRMS). Methods In this prospective paired study, newly diagnosed, untreated RRMS patients were sampled during clinical relapse and subsequent remission. A targeted miRNA panel was quantified using quantitative PCR. Differential expressions were assessed using paired statistical testing with multiple comparison correction. Diagnostic performance was evaluated using ROC analysis and multivariate logistic regression. Pathway enrichment analysis was performed using Ingenuity Pathway Analysis. Results Twenty patients (40 paired samples) were included. Eight miRNAs were differentially expressed between relapse and remission after Benjamini–Hochberg correction. hsa-miR-122-5p showed the largest fold change (fold change = 3.0; adjusted p = 0.043). A three-miRNA panel (hsa-miR-122-5p, hsa-miR-15b-5p, hsa-miR-30e-5p) demonstrated high discriminative accuracy (area under the curve = 0.88; 95% CI 0.79–0.96). Pathway analysis highlighted inflammatory, metabolic, and hypoxia-related processes. Conclusions Circulating miRNAs distinguished relapse from remission in treatment-naive RRMS patients, suggesting their potential as complementary biomarkers of disease activity. These findings should be considered exploratory and require validation in an independent, larger cohort.
Characterizing Dysphagia: Eating Assessment Tool-10 Severity Categories After Cervical Spine Surgery
Tippins, Nicholas P., Foreit, Anne M., Alentado, Vincent J., Rezner, Aidan C., Hannon, Kathleen M., Porche, Ken, Ef, Bisson, Foley, Kevin T., Potts, Eric A. , Alentado, Vincent J. , Porche, Ken, Bisson, Erica F. , Foley, Kevin T.

Neurosurgery | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004161 | PMID 42489449 Get It

BACKGROUND AND OBJECTIVES: This study proposes and assesses the validity of postoperative dysphagia severity categories based on patients' Eating Assessment Tool-10 (EAT-10) scores and quality-of-life patient-reported outcome measures (PROMs) collected before and after cervical spine surgery. METHODS: A prospectively collected multi-institutional quality registry including 2003 patients was retrospectively reviewed. Patients were categorized based on EAT-10 score severities, with thresholds determined by existing literature and significant differences in PROMs: none (0-2), mild (3-4), moderate (5-15), and severe (16-40). Correlations between EAT-10 severity and established PROMs were assessed at baseline, 3-, and 12-month follow-ups. The Dunn test using Bonferroni adjustment was used to identify differences in PROMs between EAT-10 severities. Multivariate linear regression assessed how EAT-10 severity affects PROMs at baseline, 3-, and 12-month follow-ups. RESULTS: Among 1659 patients with 3-month EAT-10 data, there were 1183 no, 149 mild, 245 moderate, and 82 severe dysphagia patients. Neck Disability Index and EuroQol 5-Dimension scores were significantly different between none vs mild ( P < .001; P = .001), mild vs moderate ( P < .001; P < .001), and moderate vs severe ( P = .035; P = .024) at 3 months. Among 1405 patients with 12-month EAT-10 data, there were 1044 no, 100 mild, 194 moderate, and 67 severe dysphagia patients. Neck Disability Index scores were significantly different between none vs mild ( P < .001) and moderate vs severe ( P = .004) but not for mild vs moderate ( P > .9) at 12 months. EuroQol 5-Dimension scores were significantly different between none vs mild ( P = .004) and mild vs moderate ( P = .005) but not for moderate vs severe ( P = .08). In multivariate regression, EAT-10 severity categories independently predicted worse PROMs at all time points. CONCLUSION: We propose none (0-2), mild (3-4), moderate (5-15), and severe (16-40) dysphagia categories based on EAT-10 scores. Evidence from univariate and multivariate analyses strengthens the validity of our proposed EAT-10 severity categories, providing statistical justification for their incorporation into clinical practice.
Distinguishing Acute Myocardial Infarction from Other Forms of Cardiac Injury with the Cardiac Troponin Long-T ITC Complex and High-Sensitivity Troponin I and T in Patients with Suspected Acute Coronary Syndrome: MERITnI Substudy
Apple, Fred S, Wagner, Barret P., Sandoval, Yader, Smith, Stephen W, Brown, Hannah M. , Miller, Joshua R, Sexter, Anne, Schulz, Karen, Jaffe, Allan S, Miller, Joshua R. , Buda, Kevin G , Sandoval, Yader , Brown, Hannah M , Miller, Joshua R , Apple, Fred S. , Buda, Kevin , Wagner, Barrett , Sandoval, Yader , Schulz, Karen , Jaffe, Allan S.

Clinical Chemistry | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/clinchem/hvag098 | PMID 42621672 Get It

Abstract Background We determined whether circulating cardiac troponin I–cardiac troponin T–troponin C (ITC) complex containing long-form cardiac troponin T (long-T ITC) complex and ratios of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) could differentiate myocardial infarction (MI) from chronic and acute non-MI myocardial injuries in patients with suspected acute coronary syndrome. Methods We measured long-T ITC complex, hs-cTnI, and hs-cTnT (Mindray) at 0- and 2-h in consecutive patients enrolled in the Mindray hs-cTnI Assay Analytical and Clinical Evaluation for the Diagnosis and RIsk Assessment of Myocardial InfarctIon (MERITnI) trial. Results Among the 882 subjects studied (median 3.0 h presentation), 47 had acute MI (5.3%), 116 had acute non-MI myocardial injury, and 90 had chronic myocardial injury. At 0 and 2 h, areas under the curve (AUC) significantly differentiated acute MI from chronic myocardial injury for long-T ITC complex (0.72 and 0.81, respectively; P = 0.0082) but not acute non-MI myocardial injury (AUC, 0.65 and 0.69, respectively; P = 0.23). 0 and 2 h AUCs for long-T ITC complex/hs-cTnT and hs-cTnI/hs-cTnT ratios also significantly differentiated acute MI from chronic myocardial injury (AUC, 0.79 and 0.86, respectively) and acute non-MI myocardial injury (AUC, 0.68 and 0.71, respectively). There was no biomarker concentration or ratio value discrimination between type 1 and type 2 MIs. Conclusions Long-T ITC concentrations and long-T ITC complex/hs-cTnT and hs-cTnI/hs-cTnT ratios may clinically assist in differentiating acute MI from non-MI myocardial injuries when evaluating patients with suspected acute coronary syndrome. ClinicalTrials.gov Registration Number: NCT05853042.
Listening to the Right Ventricle: Invasive Hemodynamics to Refine Risk Before Ventricular Tachycardia Ablation
Haq, Ikram-Ul , Siontis, Konstantinos C. , Haq, Ikram U

Journal of Cardiovascular Electrophysiology | July 23, 2026 | Volume: 37 | Issue: 8 | Pages: 1709-1710

10.1111/jce.70442 | PMID 42489247 Get It

Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy
Tersalvi, Gregorio , Bois, Melanie C. , Scott, Christopher G. , Carey, Patricia , Garmany, Armin , Davies, Daniel R. , HOFFMAN, Andrew C., Zhang, Jun , Hruska, Carrie B. , Jouni, Hayan, Rodriguez-Porcel, Martin G., Askew, J. Wells , Bois, John P. , Young, Kathleen A. , Anavekar, Nandan S., CHANG, IAN C., Grogan, Martha , Maleszewski, Joseph J. , Homb, Andrew, Redfield, Margaret M. , Dispenzieri, Angela , Maleszewski, Joseph J , Homb, Andrew C, Redfield, Margaret M , Chareonthaitawee, Panithaya , Johnson, Geoffrey B , AbouEzzeddine, Omar F , Hruska, Carrie B , Scott, Christopher , Tersalvi, Gregorio , Carey, Patricia , Rodriguez‐Porcel, Martin , Anavekar, Nandan S., Dispenzieri, Angela , Chareonthaitawee, Panithaya , Johnson, Geoffrey B. , AbouEzzeddine, Omar F.

Circulation: Cardiovascular Imaging | July 23, 2026 | Volume: 19 | Issue: 8 | Pages: No page available

10.1161/circimaging.126.019832 | PMID 42488949 Get It

BACKGROUND: Technetium-based cardiac amyloid radionuclide imaging enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but conventional planar and visual semiquantitative approaches have important limitations. We developed the quantitative 3-dimensional Mayo 3D Score, defined as the ratio of mean left ventricular myocardial radiotracer uptake to right atrial blood-pool uptake using computed tomography (CT)-fused single-photon emission CT (SPECT) volumes of interest, and sought to validate its diagnostic performance against myocardial pathology. METHODS: Consecutive patients who underwent 99m Tc-pyrophosphate SPECT/CT at Mayo Clinic for suspected ATTR-CM between June 2017 and January 2025 with archived myocardial tissue were included. Baseline characteristics, including demographics, echocardiogram, biomarkers, visual semiquantitative, and Mayo 3D Score metrics, were collected. Myocardial specimens underwent histopathologic confirmation of amyloid, with amyloid subtype determination and further semiquantitative grading of amyloid burden and deposition patterns. RESULTS: Among 230 patients (median age, 72 years; 78% male), 107 (47%) had ATTR-CM, of whom 9 had hereditary ATTR-CM. The Mayo 3D Score showed excellent discrimination against pathology (area under the receiver operating characteristic curve, 0.92 [0.88–0.96]), exceeding planar Perugini (0.87 [0.83–0.92]; P =0.006), and heart-to-contralateral lung ratio (0.86 [0.81–0.91]; P =0.004) and comparable to SPECT Perugini (0.90 [0.86–0.94]; P =0.12). A cutoff ≥1.0 yielded 86.0% sensitivity, 92.7% specificity, 91.1% positive predictive value, and 88.4% negative predictive value. Among ATTR-positive cases, the Mayo 3D Score correlated strongly with semiquantitative amyloid burden (Spearman ρ=0.69), was higher in pericellular than nodular deposition patterns ( P <0.001), and was not associated with vascular involvement ( P =0.42). CONCLUSIONS: In patients with suspected ATTR-CM undergoing 99m Tc-pyrophosphate SPECT/CT, the Mayo 3D Score demonstrated superior diagnostic performance compared with planar metrics and comparable to SPECT Perugini, while correlating with myocardial ATTR burden and deposition patterns on pathology. These findings support its integration as a quantitative adjunct within clinical diagnostic ATTR-CM workflows.
Association of Mechanical Circulatory Support With In‐Hospital Outcomes in Non‐Ischemic Cardiogenic Shock: A Nationwide Inpatient Study
Liu, Li , Memon, Burhan, Zou, Tian , Elkhatib, Wiaam , Luo, Pincheng , Billstein, Laura , Kumar, Nomesh , Cheng, Youyou , Fickel, Abigail, Shao, Shengtong, Guglin, Maya, Liu, Li , Billstein, Laura E, Sun, Chenyu , Elkhatib, Wiaam Y , Fickel, Abigail, Shao, Shengtong, Guglin, Maya, Sun, Chenyu

Clinical Cardiology | July 23, 2026 | Volume: 49 | Issue: 7 | Pages: No page available

10.1002/clc.70416 | PMID 42487621 Get It

ABSTRACT Introduction Cardiogenic shock (CS) carries high morbidity and mortality. However, evidence for mechanical circulatory support (MCS) in non‐ischemic CS remains limited, as prior trials have focused on infarct‐related shock. Methods We performed a retrospective cross‐sectional study using the Nationwide Inpatient Sample (2017–2019), identifying hospitalizations with a principal diagnosis of CS and excluding acute myocardial infarction. Patients were categorized into mutually exclusive groups: no MCS, intra‐aortic balloon pump (IABP) only, Impella only, or extracorporeal membrane oxygenation (ECMO) only. Primary outcomes were in‐hospital mortality, length of stay (LOS), and total hospital cost. Survey‐weighted multivariable models adjusted for demographics, hospital characteristics, and comorbidity burden using Elixhauser and Charlson indices. Results Among 104 045 hospitalizations, 6040 received MCS. IABP was most common, followed by Impella and ECMO. Among patients receiving a single MCS strategy, overall in‐hospital mortality was 29.5%., with lower mortality in the IABP group (19.9%) compared with Impella (37.4%) and ECMO (44.3%). After adjustment, IABP was associated with lower observed in‐hospital mortality versus no MCS (aOR 0.58, 95% CI 0.53–0.64; p < 0.01), whereas Impella and ECMO showed increased aOR. IABP and ECMO were associated with longer LOS, while Impella was not. All MCS strategies were associated with higher costs, with ECMO showing the greatest increase (cost ratio 3.30, 95% CI 3.12–3.50). Conclusion In non‐ischemic CS, MCS strategies demonstrate distinct profiles of mortality and resource utilization. IABP was associated with lower observed in‐hospital mortality, whereas all MCS were linked to higher costs, highlighting heterogeneity in outcomes and the need for further research.
Advances in Semantic Web
Holford, Matthew, Cheung, Kei‐Hoi, Zheng, Mingna, King, T. A. , Krauthammer, Michael O. , Chute, Christopher G.

No container title available | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.4236/9781618962648 Get It

<p class="MsoNormal"> <span lang="EN-US">The Semantic Web has the ultimate goal of making a machine understand Internet data. To enable the encoding of semantics with the data, well-known technologies are used such as RDF (Resource Description Framework) and OWL (Web Ontology Language). These technologies formally represent the meaning involved in information. For example, ontology can describe concepts, relationships between things, and categories of things. These embedded semantics offer significant advantages such as reasoning over data and dealing with heterogeneous data sources.<o:p></o:p></span> </p>
Current Burden of Hepatitis B Virus Infection in the United States, 2017–2023
Kim, Donghee , Ahmed, Aijaz, Kim, Donghee , Danpanichkul, Pojsakorn , Wijarnpreecha, Karn , Ahmed, Aijaz

Clinical and Molecular Hepatology | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3350/cmh.2026.0817 | PMID 42487579 Get It

Advances in Hypothyroidism
Ashrafian, Hasan, Sara, Jaskanwal Deep Singh , Pan, Rui , Nguyen, Nhu-Tram A., Zhang, Ming , Pan, Rui Y., Lewandowski, Krzysztof Cezary

No container title available | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.4236/9781618962665 Get It

Hypothyroidism, also called&nbsp;underactive thyroid&nbsp;or&nbsp;low thyroid, is a&nbsp;disorder of the endocrine system&nbsp;in which the&nbsp;thyroid gland&nbsp;does not produce enough&nbsp;thyroid hormone.&nbsp;It can cause a number of symptoms, such as&nbsp;poor ability to tolerate cold, a&nbsp;feeling of tiredness,&nbsp;constipation,&nbsp;depression, and&nbsp;weight gain.&nbsp;Occasionally there may be swelling of the front part of the neck due to&nbsp;goiter.&nbsp;Untreated cases of hypothyroidism during&nbsp;pregnancy&nbsp;can lead to delays in&nbsp;growth and intellectual development&nbsp;in the baby or&nbsp;congenital iodine deficiency syndrome.<br /> Worldwide,&nbsp;too little iodine&nbsp;in the diet is the most common cause of hypothyroidism.&nbsp;Hashimoto's thyroiditis&nbsp;is the most common cause of hypothyroidism in countries with sufficient dietary iodine.&nbsp;Less common causes include previous treatment with&nbsp;radioactive iodine, injury to the&nbsp;hypothalamus&nbsp;or the&nbsp;anterior pituitary&nbsp;gland, certain medications,&nbsp;a lack of a functioning thyroid at birth, or previous&nbsp;thyroid surgery.&nbsp;The diagnosis of hypothyroidism, when suspected, can be confirmed with&nbsp;blood tests&nbsp;measuring&nbsp;thyroid-stimulating hormone&nbsp;(TSH) and&nbsp;thyroxine&nbsp;levels.